Metagenomi Inc

For the period ended Jun 30, 2024. Filed Aug 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 14, 2024

MGX$0.70-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

	Three Months EndedJune 30,		Six Months EndedJune 30,
	2024	2023	2024	2023
Collaboration revenue	$20,008	$11,337	$31,167	$19,994
Operating expenses:
Research and development	28,320	22,681	59,759	42,811
General and administrative	8,551	6,619	17,303	13,084
Total operating expenses	36,871	29,300	77,062	55,895
Loss from operations	(16,863)	(17,963)	(45,895)	(35,901)
Other income (expense):
Interest income	3,976	3,967	7,910	7,970
Change in fair value of long-term investments	—	2,870	—	2,870
Other income (expense), net	(51)	16	(101)	15
Total other income, net	3,925	6,853	7,809	10,855
Net loss before benefit (provision) for income taxes	(12,938)	(11,110)	(38,086)	(25,046)
Benefit (provision) for income taxes	2,199	(1,898)	2,199	(4,095)
Net loss	$(10,739)	$(13,008)	$(35,887)	$(29,141)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale marketable securities	13	(176)	(168)	(155)
Comprehensive loss	$(10,726)	$(13,184)	$(36,055)	$(29,296)
Net loss per share attributable to common stockholders, basic and diluted	$(0.29)	$(3.82)	$(1.24)	$(8.56)
Weighted average common shares outstanding, basic and diluted	36,625,291	3,404,585	28,901,399	3,404,585

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.